Jonathan E. Alpert, MD, PhD

How can psychiatric clinicians improve outcomes for this unique patient population?

A range of therapeutic targets are likely to be relevant for reducing risk of suicide in TRD. Here's what you need to know.

Gepirone, the first and only oral selective 5HT1a receptor agonist for the treatment of major depressive disorder in adults, is expected to arrive in early 2024.

Although depression is more prevalent among women, it may be more challenging to diagnose in men. This National Men’s Health Month, learn to recognize male depression’s symptoms and catch its comorbidities.

Investigators used machine learning to derive a unique electroencephalographic pattern or “signature” that appears to predict response to antidepressants vs. placebo.

Although the current generation of antidepressants extends back to the late 1980s, efforts to describe the dose-response relationship for treatment of major depressive disorder continue. More in this research update.

With their early age of onset, high prevalence, chronicity, and pervasive impact on multiple domains of functioning, the burden of mood disorders exceeds that of virtually all medical conditions in the US and globally in terms of disability, cost, and suffering.